Managing Refusal or Withdrawal of Consent in Clinical Trials

One of the most fundamental ethical principles in clinical research is the participant’s right to refuse or withdraw consent at any point—without penalty or loss of benefit. Handling consent refusals and withdrawals appropriately is crucial for protecting participant autonomy, maintaining Good Clinical Practice (GCP), and ensuring regulatory compliance. This guide outlines step-by-step procedures for clinical trial professionals to follow when participants decline or withdraw from a study.

Understanding the Right to Withdraw Consent:

As per ICH-GCP E6(R2), participants must be informed that they:

• Are not obligated to participate
• Can withdraw at any time without giving a reason
• Will not lose access to medical care or benefits due to withdrawal

This right must be clearly stated in the informed consent form (ICF) and reinforced during the consent discussion. Regulatory agencies like USFDA and CDSCO require sponsors and investigators to uphold this principle throughout the study.

Refusal to Participate at Screening Stage:

When a participant refuses to sign the ICF:

• Respect the decision and end the screening process
• Do not collect or retain any personal medical data
• Document in screening log: “Refused consent – no participation”
• Do not record identifiable data in source or electronic systems

Ensure no coercion, persuasion, or repeated requests occur after refusal.

Withdrawal of Consent After Enrollment:

If a participant chooses to withdraw after providing initial consent:

1. Engage in a respectful discussion to understand the reason (voluntarily)
2. Clarify whether they are withdrawing from:
   • Treatment only
   • Further follow-up
   • Use of previously collected data
3. Inform them of potential consequences (e.g., data already collected may still be used unless they explicitly decline)
4. Confirm withdrawal in writing if possible (signed “Consent Withdrawal Form”)
5. Document all discussions and decisions in source notes

Maintain a copy of the withdrawal documentation in the Investigator Site File (ISF) per pharma SOP documentation.

Participant Rights and Data Handling:

Regulations vary slightly by region, but generally:

• Data collected before withdrawal can be used unless the participant requests destruction
• New data must not be collected post-withdrawal
• Samples already processed may not be retrievable
• Use of identifiable data post-withdrawal must be stopped if participant requests it

Consult the protocol, Ethics Committee guidelines, and local regulations before making final decisions.

GCP-Compliant Documentation of Withdrawal:

Accurate, neutral, and complete documentation is essential. Include:

• Date of withdrawal
• Person documenting the event
• Participant statement or signed withdrawal form
• Any remaining follow-up or safety data collection agreed upon
• Updates to the Informed Consent Log and subject status

Ensure logs and source notes align with the GMP audit checklist and trial master file structure.

Notifying Relevant Stakeholders:

• Inform the study monitor and sponsor immediately
• Notify the Ethics Committee if required by local policy
• Submit an update via the EDC or IVRS/IWRS system
• Adjust visit schedules and drug accountability accordingly

Review trial-specific guidance or sponsor SOPs for additional notification timelines.

Handling Safety Follow-Up Post Withdrawal:

In certain cases, the protocol may recommend follow-up for safety even after withdrawal. If the participant agrees:

• Obtain separate consent (verbal or written, depending on the protocol)
• Limit procedures strictly to safety assessments
• Document this separately in the source and consent log

If the participant refuses any further involvement, no procedures should be conducted.

Withdrawal in Vulnerable Populations:

For children, elderly, or cognitively impaired subjects:

• Guardians or legally authorized representatives (LARs) must be involved
• Assent withdrawal from children must also be respected, even if parents consent
• Document all conversations in the presence of impartial witnesses when appropriate

These scenarios must be handled in accordance with validation protocols for re-consent or termination.

Common Pitfalls and How to Avoid Them:

• Error: Continuing procedures after consent withdrawal
  
  Fix: Immediately cease all study-related activities
• Error: Using non-approved forms to document withdrawal
  
  Fix: Use Ethics Committee-approved templates
• Error: Failing to notify sponsor or update logs
  
  Fix: Follow your site’s SOP and trial-specific checklist
• Error: Deleting data without participant request
  
  Fix: Retain unless participant specifically requests removal

Checklist for Managing Consent Refusal or Withdrawal:

1. Respect participant decision and end engagement
2. Clarify scope of withdrawal (full, partial, or data only)
3. Document event clearly in source notes and logs
4. Update ICF log, drug return, and CRF systems
5. Inform sponsor, monitor, and EC (if required)
6. Ensure all site staff are informed of the status

Conclusion:

Refusal or withdrawal of consent is not a deviation—it is a protected right. Ethical and regulatory compliance requires that clinical trial teams respond with clarity, compassion, and precision. With the right SOPs, documentation practices, and staff training, sponsors and sites can manage withdrawals effectively while maintaining the integrity of both participant rights and trial data.